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Apoptotic cell-derived ICAM-3 promotes both
macrophage chemoattraction to and tethering
of apoptotic cells
EE Torr1, DH Gardner1, L Thomas1, DM Goodall2, A Bielemeier1, R Willetts1, HR Griffiths1,3, LJ Marshall1,3 and A Devitt*,1,3
A wide range of molecules acting as apoptotic cell-associated ligands, phagocyte-associated receptors or soluble bridging
molecules have been implicated within the complex sequential processes that result in phagocytosis and degradation of
apoptotic cells. Intercellular adhesion molecule 3 (ICAM-3, also known as CD50), a human leukocyte-restricted immunoglobulin
super-family (IgSF) member, has previously been implicated in apoptotic cell clearance, although its precise role in the clearance
process is ill defined. The main objective of this work is to further characterise the function of ICAM-3 in the removal of apoptotic
cells. Using a range of novel anti-ICAM-3 monoclonal antibodies (mAbs), including one (MA4) that blocks apoptotic cell clearance
by macrophages, alongside apoptotic human leukocytes that are normal or deficient for ICAM-3, we demonstrate that ICAM-3
promotes a domain 1–2-dependent tethering interaction with phagocytes. Furthermore, we demonstrate an apoptosis-associated
reduction in ICAM-3 that results from release of ICAM-3 within microparticles that potently attract macrophages to apoptotic
cells. Taken together, these data suggest that apoptotic cell-derived microparticles bearing ICAM-3 promote macrophage
chemoattraction to sites of leukocyte cell death and that ICAM-3 mediates subsequent cell corpse tethering to macrophages. The
defined function of ICAM-3 in these processes and profound defect in chemotaxis noted to ICAM-3-deficient microparticles
suggest that ICAM-3 may be an important adhesion molecule involved in chemotaxis to apoptotic human leukocytes.
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Cells undergoing programmed cell death (apoptosis) are
efficiently removed by phagocytes in a process important for
development, tissue maintenance and control of immune
responses. Whereas neighbouring viable cells may remove
low levels of local cell death, professional recruited macro-
phages deal with high levels of apoptotic death. Failure to
effectively clear dying cells has been implicated in a range of
pathological scenarios.1–3
The molecular mechanisms that underlie phagocyte re-
cognition and clearance of apoptotic cells are still under
investigation, although a wide range of phagocyte receptors
and amore limited number of apoptotic cell-surfacemolecules
have been defined.2,4 These molecules participate in a
multistage process that, at least in the case of recruited
professional phagocytes, involves recruitment through che-
motaxis5–8 before apoptotic cell recognition, tethering and
phagocytosis, all of which are accompanied by immunomo-
dulatory signalling. Themost widely established change at the
apoptotic cell surface is exposure of the aminophospholipid
phosphatidylserine (PS) that mediates clearance.9–11 How-
ever, other less well-defined changes indicate an involvement
of sugars,12–14, PS oxidation15 and exposure of intracellular
components (e.g., annexin I).16 Previous work suggested that
the immunoglobulin super-family (IgSF) member intercellular-
adhesion molecule (ICAM)-3, expressed on human leuko-
cytes, becomes functionally altered during apoptosis to
mediate clearance of apoptotic leukocytes through suggested
generation of neo-epitopes (i.e., ‘eat me’ signals).17 However,
more recently, a study of CD31, another IgSF member,
suggests that molecules on viable cells may provide inhibitory
signals18 that are lost during apoptosis, permitting viable
cellular interactions (e.g., CD31–CD31 in trans) to become
functional phagocytic interactions.18–20 CD47 may also
mediate such inhibitory signals.21–23 It seems likely that loss
of inhibitory signals and gain of neo-epitopes occur at the
apoptotic cell surface and together facilitate cell removal.
However, the role and nature of apoptotic cell-associated
ICAM-3 in the multistep process of apoptotic cell clearance
have remained elusive.
Here we show apoptotic cell-associated ICAM-3 functions
in tethering apoptotic cells to phagocytes. However, during
apoptosis it is known that levels of surface proteins may be
reduced through loss of membrane into apoptotic bodies
(microparticles).24 Such microparticles from apoptotic B cells
have been shown to have strong chemoattractive properties24
in a manner dependent upon the chemokine fractalkine
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(CX3CL1), which acts as a ‘find me’ signal, and its cognate
receptor (CX3CR1).25 Here we show that rapid and sub-
stantial loss of ICAM-3 from the surface of apoptotic
leukocytes occurs via microparticle shedding and these
microparticles are strongly chemoattractive in a manner
dependent upon ICAM-3. Together with the established role
of ICAM-3 as an important adhesion molecule involved in
immune synapse formation, our data provide new insight into
the mechanisms of chemoattraction of phagocytes to apopto-
tic cells and identify ICAM-3 as a key adhesion molecule
within the process.
Results
Interaction of apoptotic cells with phagocytes is inhi-
bited by ICAM-3 mAb MA4. Moffatt et al.17 characterised
two, now unavailable, anti-ICAM-3 monoclonal antibodies
(mAbs: BU68 and 3A9) capable of blocking interaction of
apoptotic cells with phagocytes showing that they were
reactive to the membrane-distal domains of ICAM-3
(domains 1 and 2). Here a panel of novel mAbs raised
from mice immunised with ICAM-3-transfected human
embryonic kidney (HEK) cells were screened by ELISA
against recombinant ICAM-3 (domains 1 and 2)-Fc fusion
protein and CD14-Fc as a control (Supplementary Figure 1).
We identified 17 anti-ICAM-3 mAbs specific for domains 1
and 2.
Using an established model system of specific apoptotic
cell clearance,26,27 we screened these anti-ICAM-3mAbs and
identified one, MA4, that robustly inhibited apoptotic cell
interaction with phagocytes (Figures 1a and b). The observed
degree of inhibition with MA4 (59±14%) was in line with that
seen previously with ICAM-3 mAbs BU68 and 3A9.17 Other
mAbs (e.g., BH10 and GD12) of the same isotype (murine
IgG1/k) were also screened but failed to inhibit clearance.
Further analyses indicated that MA4, BH10 andGD12were all
capable of reacting with full-length ICAM-3 (domains 15) that
was denatured and reduced (assessed by western blotting) or
native and cell-associated ICAM-3 (assessed by flow cyto-
metry) (Supplementary Figure 1).
These results confirm MA4 as a novel anti-ICAM-3 mAb
that reacts with a probable linear epitope in domains 1 and 2 of
ICAM-3, and is capable of inhibiting apoptotic cell interaction
with phagocytes.
Apoptotic cells deficient for ICAM-3 exhibit reduced
clearance by phagocytes. Earlier studies showed that the
role of ICAM-3 on apoptotic cells in promoting clearance can
be revealed through the use of inhibitory mAbs (Figure 1a,
and see Moffatt et al.17) and by overexpression of ICAM-3 to
promote clearance.17 Here we demonstrate an alternative
and complementary method to reveal a role for ICAM-3 in
apoptotic cell clearance. ICAM-3-deficient Mutu Burkitt’s
lymphoma (BL) cells or Jurkat T cells (human leukocyte
cell lines that normally express ICAM-3) were isolated
following sequential flow cytometric sorting for very low/
negative expression levels of surface ICAM-3. The cellular
proteome analysed by 2D gel electrophoresis28 was not
significantly different between ICAM-3-deficient cells and
their ICAM-3-replete counterparts. Such ICAM-3-deficient
cells exhibited reduced ability to interact with THP-1 phago-
cytes when compared with their ICAM-3-replete counterparts
(Figure 2a). Similar results were noted with primary human
monocyte-derived macrophages (Supplementary Figure 2).
Detailed analysis of apoptotic cell death indicated that both
populations of cells died with the same kinetics and to
the same extent irrespective of their ICAM-3 expression
(Supplementary Figure 3). Furthermore, when apoptotic cells
were incubated with phagocytes in the presence of MA4, only
the recognition of ICAM-3-expressing cells was inhibited
Figure 1 Inhibition of apoptotic cell interaction with THP-1 phagocytes by anti-
ICAM-3 mAb MA4. (a) Mutu BL cells were induced to apoptosis by UV (100 mJ/cm2)
and co-cultured with THP-1 phagocytes (MØ) in the presence of the indicated
mAbs. The proportion of MØ interacting with (tethering and/or phagocytosing)
apoptotic cells (ACs) was scored using light microscopy following Jenner/Giemsa
staining. Data (mean±S.D.) from at least three separate experiments each carried
out in quadruplicate are shown (data are normalised to the mAb-free co-culture
(‘Alone’). (b) Microscopic appearance of a THP-1 phagocyte culture or co-cultures
of THP-1 and ACs in the presence or absence of the indicated mAb (MA4 or BH10).
Scale bar¼ 50mm. **Po0.01 ANOVA with Dunnett’s post-hoc test
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(Figure 2c and d), supporting the specificity of effect by MA4.
This phenomenon was evident irrespective of the method
chosen for induction of apoptosis (UV (Figure 2), ionomycin
or staurosporine (data not shown)).
It is notable that ICAM-3 mediates apoptotic human
leukocyte clearance by murine macrophages (Figure 2d).
These data demonstrate that the phagocyte receptor function
for apoptotic ICAM-3 is present in mice where ICAM-3 is
naturally absent. Taken together, these data further demon-
strate a role for ICAM-3 in the interaction of apoptotic
leukocytes with phagocytes, consistent with our previous
reports, and that the receptor for apoptotic ICAM-3 likely
recognises molecular changes that may not be restricted to
ICAM-3. Indeed, these observations further support the notion
that clearance mechanisms are highly conserved across
species.
Apoptotic cell-associated ICAM-3 mediates tethering to
phagocytes. The phagocytic removal of apoptotic cells is a
complex multistep process.2 To address whether apoptotic
cell-associated ICAM-3 functions as a ligand for tethering or
engulfment, apoptotic leukocytes were co-cultured with phago-
cytes at 201C, permissive only for apoptotic cell tethering
to phagocytes,29 and results were compared with assays at
371C, permissive for both tethering and phagocytosis. Here
we show reduced tethering of ICAM-3-deficient BL cells with
human phagocytes when compared with their ICAM-3-replete
counterparts (Figure 3a). These data strongly implicate ICAM-3
as a tethering ligand for apoptotic cells, a function also demon-
strated using mouse macrophages (Figure 3b).
ICAM-3 levels reduce during apoptosis due to shedding
in microparticles. It is intriguing that ICAM-3 levels reduce
during apoptosis given the emergence of a role for ICAM-3 in
apoptotic cells.17 Mutu B cells provide a robust model for the
analysis of early apoptosis by flow cytometry. Light scatter
(forward scatter/electronic volume (FS/EV) versus side scatter
(SS)) defines two cell populations (Figure 4a): region 1: smaller
and more granular cells that are necrotic (including late
apoptotic/secondary necrotic cells) and stain with the vital
dye propidium iodide (PI); and region 2: larger and
less granular cells (live or early apoptotic) where plasma
membranes are intact and exclude PI.27,30 Region 2 cells
(live/early apoptotic) are therefore viable or actively
undergoing apoptosis (as detected by annexin V (AxV)
staining and exclusion of PI). This live/early apoptotic region
Figure 2 Interaction of apoptotic cells with human or mouse phagocytes is reduced in the absence of apoptotic ICAM-3. WT and ICAM-3-deficient BL and Jurkat cells
were induced to apoptosis by UV (Mutu: 100 mJ/cm2; Jurkat 150 mJ/cm2) and co-cultured with THP-1 phagocytes (MØ) for 1 h. The proportion of MØ interacting with (tethering
and/or phagocytosing) apoptotic cells (ACs) was scored using light microscopy following Jenner/Giemsa staining (a). Expression of ICAM-3 on apoptotic target cells was
assessed by indirect immunofluorescence. Flow cytometric histograms of anti-ICAM-3 mAb-stained WT (grey profiles) or ICAM-3-deficient (clear profiles) Mutu/BL or Jurkat
cells are shown (b). The ability of the blocking anti-ICAM-3 mAb MA4 to modulate the capacity of apoptotic WT and ICAM-3-deficient BL cells to interact with THP-1
phagocytes (c) and J774 mouse phagocytes (d) was assessed. Data shown are mean±S.D. of replicate samples (n¼ 4) from one experiment (of at least four similar).
***Po0.001 ANOVA with Tukey’s post-hoc test
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of a population of Mutu BL cells will be predominantly AxVþ /
PI within 5–6 h of UV irradiation. With continued incu-
bation, these cells change morphology to fall in region 1 (late
apoptotic/necrotic) with apoptotic nuclear morphology.27,30
In line with previous work,17 we noted ICAM-3 reduced (by
30%) in Mutu BL cells 24 h after apoptosis induction (mean
fluorescence intensity (MFI) Mutu control¼ 50.3 versus
Mutu 24 h post UV¼ 35.2). No such decrease was noted
with apoptosis-resistant Mutu/B-cell lymphoma 2 (bcl-2) cells
(MFI Mutu/bcl-2 control¼ 50 versus Mutu/bcl-2 24 h post
UV¼ 47.7). To exclude the effects of secondary necrosis
or prolonged incubation in vitro, ICAM-3 levels on early
apoptotic cells were further studied.
Here we demonstrate that ICAM-3 levels begin to reduce
in Mutu cells (but not Mutu/Bcl-2 cells) while still confined to
the live/early apoptotic region 2, suggesting that ICAM-3
levels reduce early in apoptosis (Figure 4b) and low
ICAM-3 levels are most closely associated with PS exposure
as detected with AxV-fluorescein isothiocyanate (FITC)
(Figure 4c). All cells that show low expression of ICAM-3 are
also exposing PS.
The mechanism of ICAM-3 reduction has not been
reported. A number of possible explanations for this exist
and are associated with monoclonal antibody detection of
ICAM-3. Structural alterations to ICAM-3 (e.g., changes in
glycosylation) may render mAbs unable to detect ICAM-3
even if present. Alternatively, molecular redistributions of
ICAM-3 during apoptosis may result in epitope masking such
that ICAM-3 is less detectable (via mAbs) rather than being
reduced in levels. To address this possibility, we generated a
green fluorescent protein (GFP)-tagged ICAM-3 (C terminal
tag; intracellular) and expressed this in HeLa cells. These
cells showed reduced levels of ICAM-3–GFP as apoptosis
proceeded (Figure 4d), suggesting ICAM-3 loss. Together,
the reduction in GFP and concomitant loss of cell volume
(Figure 4d) suggest that ICAM-3 levels are unlikely to be
reduced simply as a result of ICAM-3 cleavage from the cell,
leaving behind the GFP tag and transmembrane domain.
Loss of ICAM-3 as an explanation of the reduced ICAM-3
levels was also supported by the observation that lymphocyte
ICAM-3 levels (detected using immunofluorescent flow
cytometry) also showed ICAM-3 reduced with cell volume
(Figure 4e). Apoptosis-induced reduction in cell volume is
known to occur via a number of mechanisms including
membrane loss through release of blebs to apoptotic bodies
(membrane-enclosed apoptotic cell-derived material, parti-
cles also known as microparticles).
To test the hypothesis that ICAM-3 levels reduce during
apoptosis as a result of shedding within microparticles, ICAM-
3–GFP-transfected HeLa cells were studied. Importantly,
phagocytes cleared these cells in an ICAM-3-dependent
manner (revealed by MA4 inhibition of the interaction;
Supplementary Figure 4) indicating that GFP tagging of
ICAM-3 did not disrupt the function of ICAM-3 in apoptotic cell
clearance. Detailed microscopic analyses of HeLa-ICAM-3–
GFP cells throughout an established model of apoptosis31
revealed ICAM-3–GFP within blebs at the apoptotic cell
surface (Figure 5a). These blebs appeared early (beginning 2
to 3 h post anisomycin) in the apoptosis programme and in
some cases were large (up to 5 mm diameter) and contained
nuclear material (Figure 5a). Although HeLa cell apoptosis
differs in respect of membrane blebbing to that seen in
leukocytes, the blebbing noted within our studies equates to
the second wave of HeLa cell blebbing that is similar to that
seen in leukocytes.31 However, it is unclear if the observed
blebs are released. In order to assess then if such relocation of
ICAM-3 occurs in our leukocyte model of apoptosis and to
extend our observations to assess if these visualised blebs
are released from dying cells, wild-type (WT) or ICAM-3-
deficient Mutu cells were induced to apoptosis and culture
supernatants harvested. Using centrifugation to enrich for
microparticles and western blotting to detect ICAM-3, our
data indicate a clear release of ICAM-3 in microparticles
(Figure 5b).
Microparticle release from dying B cells has been reported
and is accompanied by loss of cell-surface molecules, and
those particles are reported to be chemoattractive for
macrophages.24 More recently, microparticles from Mutu BL
cells have been noted to have chemoattractive capacity to
recruit macrophages to sites of cell death in a manner, at least
partly, dependent upon the chemokine CX3CL1 and its
receptor CX3CR1.25
Given that cell recruitment often requires a chemokine and
adhesion molecule to affect cell recruitment, and that we have
here shown that ICAM-3 functions to tether dying cells to
phagocytes, we reasoned that ICAM-3 is a possible candidate
adhesion molecule involved in microparticle interaction with
macrophages, thus mediating chemoattraction. To assess
Figure 3 Tethering (binding) of apoptotic cells to human or mouse phagocytes
is reduced in the absence of apoptotic cell ICAM-3. BL and Jurkat cells (WT or
ICAM-3 deficient) were induced to apoptosis by UV (Mutu: 100 mJ/cm2; Jurkat
150 mJ/cm2). The capacity of THP-1 phagocytes to tether apoptotic cells (WT,
grey bars; ICAM-3-deficient, open bars) was assessed at room temperature
(nonpermissive for phagocytosis) and compared with interaction (binding and
phagocytosis), which was assessed at 371C (a). Similar tethering assays using J774
and RAW mouse phagocytes are shown (b). Data shown are mean±S.D. of
replicate samples (n¼ 4) from one experiment of at least three similar. **Po0.01;
***Po0.001 ANOVA with Tukey’s post-hoc test
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this, microparticles from BL cells (WT or deficient for ICAM-3)
were tested for their chemoattractive capacity in a micro-
Boyden chamber. Our data revealed a potential for micro-
particles from BL cells WT for ICAM-3 to promote phagocyte
movement (Figure 6a). Interestingly, microparticles released
from ICAM-3-deficient BL cells were significantly less potent,
suggesting a major role for ICAM-3 in this process. In order to
address the possibility that microparticles from ICAM-3-
replete cells were simply promoting chemokinesis rather than
directional movement (chemotaxis), phagocytes were
exposed to microparticles without a gradient (i.e., micro-
particles were present in both wells of the chamber). In this
case, phagocyte movement was significantly reduced
(Figure 6b), suggesting a gradient was necessary to elicit
movement of phagocytes, and confirms the chemoattractive
potential of microparticles from ICAM-3-replete cells. One
Figure 4 Cell-surface ICAM-3 levels reduce during apoptosis in line with a loss of cell volume. (a) Electronic volume versus side scatter flow cytometric dot plots
of Mutu BL cells at 0 h (left) or 24 h (right) post UV. Region 1 cells are necrotic and late apoptotic whereas region 2 cells are live or early apoptotic. (b) Mutu BL cells or
Bcl-2-transfected counterparts (Mutu/bcl-2) were irradiated with UV (100 mJ/cm2) and 4 h post UV were assessed in parallel for PS exposure (using AxV-FITC staining)
and ICAM-3 expression (using direct immunofluorescence with anti-ICAM-3-PE) of cells within zone 2 (live/early apoptotic cells). Grey profiles show staining of irradiated
cells whereas clear profiles show nonirradiated cells. UV-treated Mutu but not Mutu/bcl2 cells show high level of PS exposure and reduced levels of ICAM-3. (c) UV-induced
Mutu BL stained for both ICAM-3 expression (ICAM-3-PE) and PS exposure (AxV-FITC) shows PS-exposing cells (in region 2 – live/early apoptotic) preferentially express
reduced ICAM-3. (d) HeLa cells expressing ICAM-3–GFP were assessed for cell volume and ICAM-3–GFP expression over time following induction to apoptosis with
anisomycin (5 mg/ml). (e) Mutu BL cells were induced to apoptosis with UV and the percentage of cells positive for ICAM-3 (assessed using anti-ICAM-3-PE and flow
cytometry) was compared with cell volume (electronic volume (EV)) and PS exposure (AxV). Data shown are collected from at least 5000 events and are representative of
at least three similar experiments
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simple explanation of these results may be that cells WT for
ICAM-3 died more quickly or to a greater extent, and thus were
likely to generate more microparticles. Our studies indicated
that the kinetics and extent of death within these two cell lines
were equivalent. In order to assess generation of microparti-
cles, supernatants from apoptotic cultures of WT or ICAM-3-
deficient cells, as used in the chemoattraction assays, were
analysed by dynamic light scattering using a Zetasizer
(Malvern Instruments, Malvern, UK). Such analyses measure
particle diameter and our studies indicated no significant
difference between the generated microparticles, with both
cultures showing similar numbers and size distribution of the
particles (WT: 186±26.2nm; ICAM-3 deficient: 206±
47.7nm). Taken together, these data suggest that ICAM-3 in
microparticles supports phagocyte chemoattraction.
Discussion
Herein we further characterise the role of ICAM-3, an
established mediator of apoptotic cell clearance,17 in mediat-
ing this complex, multistage process that comprises, in vitro,
recognition (to enable specific identification of dying cells),
binding/tethering (a strong cell–cell interaction), phagocyte
signalling (to initiate the next phase of the process),
phagocytosis (reorganisation of cytoskeleton and mem-
brane for uptake) and finally degradation. In vivo, however,
it may be necessary for phagocytes to seek dying cells
and here we consider the role of ICAM-3 within the whole
clearance process.
Here we report a novel mAb, MA4, that reacts with domains
1 and 2 of ICAM-3 and blocks interaction of apoptotic
leukocyteswithmacrophages. In addition, we have developed
cell lines deficient for ICAM-3 expression. The capacity of
these ICAM-3-deficient cells, when apoptotic, for clearance by
macrophages is reduced compared with their ICAM-3-replete
counterparts and provides another powerful tool for ICAM-3
analysis. These ICAM-3-deficient cells complement pre-
viously described overexpression studies in HEK-293 cells
where exogenous ICAM-3 expression promotes apoptotic cell
clearance.17 Using these tools we demonstrate that ICAM-3
promotes apoptotic cell clearance by, at least minimally,
tethering cell corpses to phagocytes. However, a role for
ICAM-3 in mediating phagocytosis cannot be ruled out.
Apoptotic cell clearance has been suggested to occur
through the development of a complex phagocytic synapse
between phagocytes and dying cells,1 which is conceptually
similar to the ICAM-3-containing immune synapse between
T cells and antigen-presenting cells. This synapse also
shares similarities with the sequential development of cell–
cell interactions required for efficient leukocyte–endothelial
cell interaction before extravasation; here, weak interactions
Figure 5 ICAM-3 is present in apoptotic blebs during zeiosis and is released
from apoptotic cells in microparticles. (a) HeLa cells transfected with ICAM-3–GFP
were imaged using epifluorescence microscopy following apoptosis induction with
anisomycin (5 mg/ml). Cell nuclei were stained with DAPI (250 ng/ml) and optical
sections photographed and deconvoluted with Volocity software (PerkinElmer).
Images shown are noninduced and 3 h post anisomycin. Images were selected
to demonstrate the location of ICAM-3. Apoptotic cells expressing high levels of
ICAM-3–GFP are shown to clearly reveal the location of ICAM-3 on blebs.
Quantitative data relating to ICAM-3 expression are provided in Figure 4. (b) Mutu
BL cells (WT or ICAM-3 deficient) were UV induced to apoptosis and 16 h post-UV
culture supernatants harvested. Cell bodies were removed and discarded following
low-speed centrifugation (7 min; 350 g) and remaining microparticles purified
through high-speed centrifugation. Pelleted microparticles were prepared and
separated by PAGE and a western blot probed with anti-ICAM-3 mAb MA4.
Scale bar¼ 16mm
Figure 6 Microparticles from apoptotic cells mediate macrophage chemoat-
traction in an ICAM-3-dependent manner. Microparticles were prepared from
cultures of apoptotic Mutu BL cells (WT or ICAM-3 deficient) at 16 h post UV.
Supernatants were centrifuged to remove cell bodies (7 min; 350 g) and used
neat. (a) Chemotaxis assay: the bottom chamber contained microparticles whereas
the top chamber contained dihydroxyvitamin D3-stimulated THP-1 cells. Migration
was allowed to proceed for 4 h before staining of migrated cells and quantitation by
light microscopy. For each experimental treatment, four replicate wells were used
and within each five high-power fields (HPFs) of view counted to quantify the
number of migrated cells. Data shown are mean±S.E. of independent experiments
(n¼ 7). *Po0.05 ANOVA with Tukey’s post-hoc test. (b) Chemokinesis control
where the chemotactic gradient was disrupted via inclusion of microparticles in both
upper and lower chambers. Data shown are mean±S.E. of independent
experiments (n¼ 4). *Po0.05 ANOVA with Tukey’s post-hoc test
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lead, via signalling events, to more stable interactions utilising
b2-integrins that arrest leukocytes on vascular walls through
interaction with adhesion molecules including IgSF members.
Such comparisons may be of significant relevance when
describing the nature of the apoptotic cell–phagocyte inter-
action process, especially with a focus on ICAM-3, a further
IgSF member that is leukocyte restricted.
The demonstration that ICAM-3 functions, on the apoptotic
cell, as an adhesion molecule promoting the tethering of
apoptotic leukocytes in a manner that is at least partially
nonredundant is novel and expands our knowledge as to the
involvement of the IgSF in this clearance process. Further-
more, it may provide useful evidence for the identification of
the specific receptor that may be involved in the recognition of
apoptotic cell-associated ICAM-3, a receptor that to date has
proved elusive.
An intriguing aspect to ICAM-3 is its reduction in expression
during apoptosis despite its novel tethering role in clearance.17
We show that this reduction in ICAM-3 is rapid and extensive.
Apoptosis-associated disruption/masking of epitopes through
molecular associations (e.g., ICAM-3 associations with itself or
other molecules) or molecular changes (e.g., alterations in
glycosylation) could reveal apparent reductions in ICAM-3 via
mAb-based detection. Furthermore, shedding of ICAM-3
extracellular domains as a soluble cleavage product or release
in apoptotic bodies may explain such observations. Here we
used ICAM-3–GFP to monitor ICAM-3 directly and demon-
strate in transfected HeLa cells that ICAM-3 is present within
surface blebs during apoptosis. This experimental system with
exogenous expression of a tagged ICAM-3 within HeLa cells
demonstrated that an intracellular GFP tag did not disrupt the
ability of ICAM-3 to function as a tethering ligand on apoptotic
cells. Notably, although overexpression may increase the
removal of apoptotic non-leukocytes (HEK cells),17 it some-
times failed to increase tethering to phagocytes but simply
introduced a new tethering mechanism, now inhibitable with
anti-ICAM-3 mAb MA4.
The outcome of cell–cell interactions is dictated by the net
effect of multiple systems acting between cells, including
molecules that promote clearance and molecules that inhibit
clearance. Notably, ICAM-3 is present in both viable and
apoptotic leukocytes, although viable leukocytes are not
tethered or engulfed by phagocytes.17 The novel role in
corpse tethering and clearance for apoptotic cell-associated
ICAM-3 is likely associated with a loss of molecules such as
CD31 and CD47 that exert inhibitory effects to prevent viable
cell clearance18,21 andmay also include qualitative changes in
ICAM-3 as cells proceed through apoptosis. Future work may
assess the potential for native ICAM-3 on viable cells to act in
an inhibitory manner similar to its close relative CD31.
Our evidence that ICAM-3 levels on leukocytes were
reduced in line with reductions in cell volume and the
observations of ICAM-3 within apoptotic ICAM-3-transfected
HeLa cell blebs led us to identify ICAM-3 within microparticles
released from apoptotic leukocytes. Suchmembrane loss has
been demonstrated previously and is more than a simple
phenomenon associated with poor membrane and cytoske-
letal regulation during death. It is an important functional event
for dying cells involved in phagocyte recruitment to undertake
the final clearance step of the apoptosis programme.24
Microparticles from apoptotic BL cells, as used in our studies,
have been reported to be important in monocyte recruitment
to B-cell apoptosis in a manner that is CX3CL1 (fractalkine)
dependent.25 CX3CL1 is a novel class of chemokine with
adhesion properties, suggesting that it may play a dual role in
monocyte recruitment, acting as both chemokine and adhe-
sion molecule. Our data suggest that ICAM-3, a classical
adhesion molecule, may also function within this process as
ICAM-3-containing microparticles are significantly more
potent in recruiting macrophages than their ICAM-3-deficient
counterparts. Given our described role for ICAM-3 in tethering
apoptotic cells to phagocytes, the established role for ICAM-3
in stabilising T cell–APC interactions and the involvement of
other IgSF members (ICAM-1/2) in processes that require
chemokine signalling (e.g., leukocyte extravasation), we
propose that ICAM-3 may function as an adhesion molecule
to complement the role of CX3CL1 or other microparticle-
associated chemoattractants in recruiting phagocytes to sites
of B-cell death. Indeed, it is likely that a range of chemoat-
tractants are housed on and within complex microparticles
and these have been suggested to act as long-distance
mediators of attraction.32,33
Interestingly, evidence exists for preferential loss of ICAM-3
(54% reduction) over CD31 (18% reduction) in apoptotic
neutrophils (which lose relatively little membrane during
apoptosis relative to lymphocytes), suggesting ICAM-3 may
be preferentially released in microparticles.34 Our work
suggests this may be an active mechanism to recruit
macrophages. Further work is also needed to assess the
immunomodulatory effect of ICAM-3 and microparticles
released from apoptotic cells. Our current work indicates that
microparticles can exert anti-inflammatory effects on macro-
phages irrespective of their ICAM-3 expression, although
preliminary data suggest that ICAM-3-replete microparticles
may more rapidly exert their effect, perhaps through more
efficient interaction of microparticles with phagocytes.
Our work raises the possibility that ICAM-3 may be targeted
to modulate macrophage/monocyte recruitment to sites
where leukocyte cell death may be occurring. The athero-
sclerotic plaque, a nonresolving inflammatory site, comprises
a complex scenario of monocyte recruitment, overwhelmed
capacity for phagocytic removal of lipid-laden apoptotic
(‘foam’) cells coupled with further cell death and further
recruitment in a progressive and deleterious pathological
manner.35 Although one might expect ICAM-3 to be involved
in monocyte recruitment to apoptotic foam cells, with
monocytes expressing ICAM-3, it is perhaps even more
compelling given the observations that foam cells express
CX3CL1,36 and monocyte subsets in mice that accumulate in
plaques express and utilise CX3CR1 in their recruitment.37
Furthermore, it has recently been hypothesised that apoptotic
cell-derived chemoattractants may recruit monocytes to
tumours where as tumour-associated macrophages they play
an important role in driving tumourigenesis.33 This model
may be of great importance in the case of non-Hodgkin’s
lymphoma (e.g., Burkitt’s lymphoma from where our Mutu BL
cells derive) where high levels of apoptosis and large numbers
of macrophages coexist.33
In conclusion, we demonstrate that ICAM-3 functions at
least minimally as a ligand to tether apoptotic cells to
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phagocytes in a manner that is, at least partially, nonredun-
dant. Associated with this function is a loss of ICAM-3 during
apoptotic cell blebbing, and released ICAM-3-containing
microparticles potently recruit phagocytes via chemotaxis to
apoptotic leukocytes. Our data are consistent with ICAM-3
complementing the role of other chemoattractants (e.g.,
CX3CL1) and may function as an important adhesion
molecule within this recruitment pathway. Further work is
now needed to assess the importance of ICAM-3 in recruiting
phagocytes to sites of leukocyte cell death (e.g., athero-
sclerotic plaques and leukocyte-derived tumours) and to
characterise the exact molecular mechanisms by which it
appears to exert its effect.
Materials and Methods
Cell isolation, cell lines and culture. Anti-ICAM-3-expressing hybridoma
cells were produced by fusing spleen cells from ICAM-3/HEK transfectant17
immunised Balb/c mice with Ag8.653 cells. All work was undertaken in accordance
with regulatory guidance. Briefly, splenocytes from an immunised mouse were
fused (5 : 1 ratio) with myeloma cells in the presence of 50% PEG1500 (Roche,
Applied Science, West Sussex, UK) under serum-free conditions. Hybridomas were
cloned using limiting dilution in RPMI-1640 medium containing 2 mM L-glutamine
supplemented with 10% v/v fetal calf serum (FCS; PAA, Yeovil, UK), 100 IU/ml
penicillin and 100mg/ml streptomycin) and HAT selection supplement (Sigma,
Poole, UK). The anti-ICAM-3 reactivity of culture supernatants against immobilised
ICAM-3-Fc and CD14-Fc was assessed using ELISA.
Mutu I BL cells,38 Jurkat (human T) and THP-1 (human myelomonocytic) were
cultured in RPMI-1640 medium containing 2 mM L-glutamine supplemented
with 10% FCS (PAA) and 100 IU/ml penicillin and 100mg/ml streptomycin).
RAW 264.7 cells (murine macrophage39), J774 cells (murine macrophage40),
HeLa 229 (human epithelial) and HEK-293 cells (human epithelial) cells were
cultured similarly but in DMEM (PAA) supplemented with FCS, glutamine and
antibiotics as above.
ICAM-3-deficient Mutu I cells were generated by sequential fluorescence-
activated cell sorting of a WT Mutu I population. Briefly, cells were stained
aseptically with excess anti-ICAM-3 mAb (CAL3.10; R&D Systems, Abingdon, UK)
followed by goat anti-mouse FITC (Sigma). At least 10 000 viable cells from within
the lowest 5% fluorescence region were collected using fluorescence-activated cell
sorting. Cells were recovered in culture for 1 to 2 weeks before repeat sorting. Three
rounds of flow cytometric sorting were used to produce stable, non-ICAM-3-
expressing cell populations. ICAM-3 expression was assessed regularly using
indirect immunofluorescence to ensure no spontaneous recovery of ICAM-3 on
ICAM-3-deficient sorted populations.
Monoclonal antibody-based assays. Monoclonal antibodies were
produced as outlined above and clones of interest were further cultured and
tissue culture supernatant harvested from static cultures when cells were þ 70%
apoptotic. Such tissue culture supernatants were routinely used for subsequent
analyses.
For ELISA, Nunclon Maxisorp plates (Thermo-Fisher Scientific, Loughborough,
UK) were coated overnight with sheep anti-human Fc (The Binding Site,
Birmingham, UK) at 5mg/ml in carbonate buffer (pH 9.6; Sigma). Following
washing in PBS(T) (phosphate-buffered salineþ 0.05% v/v Tween-20), Fc-tagged
proteins were added at a concentration of 1 mg/ml for 1 h at 371C. The resultant,
oriented Fc fusions were probed with mAbs and bound mAb detected using anti-
mouse HRP (GE Healthcare, Buckinghamshire, UK) and colourimetric SigmaFAST
OPD assay (Sigma).
For western blot analysis, cells were solubilised under reducing and
denaturing conditions, separated using standard polyacrylamide gel electro-
phoresis and electroblotted to nitrocellulose (0.45mm, Schleicher & Schuell,
Dassel, Germany, supplied by Thermo-Fisher Scientific). Membranes were
blocked in 5% non-fat milk powder in TBS-tween (0.05% v/v; pH 7.2), probed
with mAbs and detected using anti-mouse HRP and ECL detection kits
(GE Healthcare).
For indirect immunofluorescence, cells were incubated with excess mAb on
ice for 30 min, washed twice in PBS(A)/BSA (0.5% w/v) and incubated with goat
anti-mouse FITC (1ml per 200 000 cells in 100ml volume; Sigma). Stained cells
were analysed either directly or following fixation in 1% w/v formaldehyde in
PBS(A) using a Beckman-Coulter Quanta SC flow cytometer (Beckman Coulter,
High Wycombe, UK). Downstream flow cytometric analyses and presentations
were undertaken using VenturiOne software from Applied Cytometry Systems
(Sheffield, UK) or FlowJo (Treestar Inc., Ashland, OR, USA).
Production of recombinant humanCD14 and ICAM-3. Recombinant
human CD14 or human ICAM-3 were produced as soluble Fc fusion proteins (fused
to CH2/CH3 domains of human IgG1).17 DNA for the recombinant proteins was
transfected to 293 cells using standard calcium phosphate-mediated transfections.
Fc fusion proteins were purified from culture supernatants using HiTrap protein G
columns (GE Healthcare).
ICAM-3–GFP (ICAM-3 with a carboxy terminal EmGFP tag) was constructed using
the Vivid Colours pcDNA6.2/C-EmGFP-GW/TOPO mammalian expression vector
(Life Technologies, Paisley, UK) as per the manufacturer’s instructions, with forward
primer: 50-ATTTAAGCTTATGGCCACCATGGTACCA-30 and reverse primer:
50-TTTTGCGGCCGCTATCATTACTTGTACAGCTCG-30. The sequence of ICAM-
3–GFP was confirmed by sequencing (Functional Genomics, Birmingham, UK). In
order to express ICAM-3–GFP in HeLa cells, DNA was transfected using the TransIT-
LT1 transfection reagent (Mirus Bio Corporation, Madison, WI, USA; supplied by
Geneflow, Fradley, Staffordshire, UK) as per the manufacturer’s instructions.
Apoptosis induction and quantification. Mutu BL or Jurkat cells were
subjected to a measured dose of UV-B irradiation, using a Chromata-vue C71 light
box and UVX radiometer (UV-P Inc., Upland, CA, USA) to induce apoptosis. BL
cells received 100 mJ/cm2 whereas Jurkats received 150 mJ/cm2. For analysis of
apoptotic nuclear morphology, cells were fixed in 1% formaldehyde, stained with
4,6-diamidino-2-phenylindole (DAPI, Sigma, 250 ng/ml) and observed using
inverted epifluorescence microscopy. For quantitative analyses, percentages of
apoptotic cells per X200 counted per sample were enumerated. HeLa cells were
induced with anisomycin (Sigma; 5 mg/ml from a stock of 5 mg/ml in DMSO). HeLa
cell apoptosis was assessed by analysis of nuclear morphology following staining
with DAPI and epifluorescence microscopy. Photomicrography was undertaken
using a fully motorised Zeiss Axiovert 200 M fluorescence microscope (Carl Zeiss
Ltd, Welwyn Garden City, Fradley, Staffordshire, UK) and Hamamatsu Orca camera
driven by Volocity (Perkin-Elmer, Cambridge, UK).
Annexin V labelling and flow cytometry. Cells were stained with
annexin V-FITC (eBioscience Ltd., Hatfield, UK). Briefly, cells were washed and
resuspended in binding buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 2.5 mM
CaCl2) containing annexin V-FITC (1 ml per 200 000 cells) for 15 min on ice. Cells
were washed once in binding buffer and diluted to 1 ml with binding buffer and PI
added to a final concentration of 20mg/ml. Samples were analysed immediately on
a Quanta SC flow cytometer (Beckman Coulter).
Assays of phagocyte interaction with apoptotic cells. Assay of
interaction (binding and phagocytosis) of phagocytes (RAW, J774 or THP-1, primary
human monocyte-derived macrophages) with apoptotic cells was carried out either
on multiwell glass slides26 or in 24-well plates as described.29 Briefly, for the slide-
based assay, apoptotic cells and phagocytes (100 : 1 ratio) were co-cultured for 1 h
at 371C in RPMI containing 0.2% (w/v) bovine serum albumin (Sigma). Unbound
cells were removed by extensive washing and slides fixed in methanol, stained with
Jenner/Giemsa (Raymond Lamb, Thermo-Fisher Scientific) and mounted in DePeX
(VWR, Lutterworth, UK) before examination by light microscopy. Assays were
performed similarly in 24-well plates but at the end of the procedure, cells were fixed
in 1% formaldehyde and stained with DiffQuick II (Medion Diagnostics GmbH,
Dudingen, Switzerland). In all cases, at least 200 macrophages were assessed in
each of at least triplicate wells. As appropriate, antibodies were included in a 1 : 10
dilution of tissue culture supernatant. For assay of binding/tethering, co-cultures
were carried out at room temperature (201C). Data are presented as percent
macrophage binding/tethering or interacting with apoptotic cells.
Where THP-1 cells were used as the phagocyte source, cells were cultured for
72 h in the presence of dihydroxyvitamin D3 (Enzo Life Sciences, Exeter, UK,
100 nM) and/or phorbol-12-myristate-13-acetate (PMA, 250 nM; Sigma) in four-well
glass slides (Hendley (Essex) Ltd, Loughton, UK). Where primary human monocyte-
derived macrophages were used, monocytes were isolated from peripheral blood of
healthy volunteers and cultured for 7 days in the presence of 10% autologous serum
in Iscove’s modified Dulbecco’s medium.26
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Isolation of microparticles and chemotaxis assays. To prepare
microparticles, viable cells were resuspended at 2 106 viable cells/ml in
serum-free RPMI supplemented with BSA (0.1%. w/v), 2 mM L-glutamine and
100 IU/ml penicillin and 100 mg/ml streptomycin. Following induction to apoptosis
and 16 h of incubation, supernatants were harvested. To remove cell bodies,
supernatants were subject to low-speed centrifugation (7 min; 350 g) and lack of
cells confirmed with microscopy. Supernatants were now used in chemotaxis
assays either neat or diluted with RPMI/BSA (0.1% w/v). To purify microparticles for
Western blot analysis, supernatants were further centrifuged (30 min;14 000 g).
For the chemotaxis assay, a 48-well chemotaxis chamber (Neuroprobe Inc.,
Gaithersburg, Madison, WI, USA) was used in line with the manufacturer’s
instructions. Briefly, 25ml of putative chemoattractant was loaded in the lower
chamber, covered with PVP-free polycarbonate membrane (5 mm pore size,
4 103 pores/mm2) and 50ml (1 105 cells) of phagocytes added to the upper
chamber. Cell migration was allowed to proceed at 371C for 4 h before washing and
staining of the membrane. Migrated cells remained adherent to the membrane
(bottom side) and were counted using light microscopy. In order to expose
phagocytes to microparticles in the absence of a concentration gradient,
microparticles were included in both chambers.
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